Articles from Boston Pharmaceuticals

Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing efimosfermin alfa, a once-monthly FGF21 analogue for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), today announced it will present results from an analysis of its Phase 2 study in participants with stage F2 and F3 fibrosis due to MASH. The findings will be presented at the European Association for the Study of the Liver (EASL) Congress 2025, May 7-10, in Amsterdam.

Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing efimosfermin alfa, an investigational, once-monthly FGF21 analogue for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), today announced it will present immunogenicity and biomarker analyses from its Phase 2 study, in participants with stage F2 and F3 fibrosis due to MASH. The results will be presented in a state-of-the-art lecture and poster at Digestive Disease Week (DDW) in San Diego, May 3-6, 2025. These findings further support the advancement of the efimosfermin clinical program to a Phase 3 pivotal study in 2025.

Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, today announced positive results from a Phase 2 study evaluating the safety and efficacy of once-monthly efimosfermin alfa (formerly known as BOS-580), a long-acting FGF21 analogue, in participants with stage F2/F3 fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH). Treatment with efimosfermin led to significant improvements in fibrosis ≥1 stage without worsening of MASH, and MASH resolution without worsening of fibrosis over 24 weeks. In the study, efimosfermin demonstrated a favorable tolerability profile. These topline results will be presented on Nov. 19 in a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting,® Nov. 15-19, 2024, in San Diego.

Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, today announced it will present key results including histologic responses from a Phase 2 study evaluating the safety and efficacy of the investigational agent, efimosfermin alfa (formerly known as BOS-580), in participants with stage F2 and F3 fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH) as a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® (Nov. 15-19, 2024 in San Diego).

Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, today announced the appointment of Margaret Koziel, M.D., as Chief Medical Officer (CMO). Juan Carlos Lopez-Talavera, M.D., Ph.D., who has served as acting CMO since December 2023, will move to an advisory role to Dr. Koziel and the Boston Pharmaceuticals team as the company advances its promising late-stage candidate BOS-580, an investigational long-acting, once-monthly fibroblast growth factor 21 (FGF21) analogue for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, today announced new Phase 2a data demonstrating the positive impact of BOS-580, an investigational, long-acting fibroblast growth factor 21 (FGF21) analogue, on the circulating lipidome and changes in the metabolomics advanced steatohepatitis fibrosis (MASEF) score in patients with phenotypic metabolic dysfunction-associated steatohepatitis (MASH). The data will be presented at the European Association for the Study of the Liver (EASL) Congress 2024, held from June 5-8 in Milan, Italy.

Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, has today named Dr. Elias Zerhouni as the new Chair of its Board of Directors, with Stefan Meister standing down from the Board after six years to focus on his ongoing roles elsewhere.

Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, today announced additional Phase 2 data supporting the low risk of immunogenicity and positive clinical effects associated with BOS-580, the company’s investigational, long-acting fibroblast growth factor 21 (FGF21) analogue for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH). The data were presented at NASH-TAG 2024 (Jan. 4-6, 2024) in Park City, Utah.

Boston Pharmaceuticals today announced the appointment of Juan Carlos Lopez-Talavera, M.D., Ph.D., as Acting Chief Medical Officer (CMO). Boston Pharmaceuticals is a clinical stage biopharmaceutical company with a lead investigational asset in non-alcoholic steatohepatitis (MASH), BOS-580, currently in Phase 2 development, and a Phase 1 asset, BOS-342, in development for hepatocellular carcinoma.

Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, today announced new data supporting BOS-580, its investigational, long-acting fibroblast growth factor 21 (FGF21) analog for the treatment of non-alcoholic steatohepatitis (NASH). Results support a once-monthly dosing schedule for BOS-580 and the positive effects of treatment for people living with NASH who are at risk for or have type 2 diabetes. These data are being presented on Saturday, Nov. 11, 2023, at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® in Boston.

Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, today announced it will present new data supporting its long-acting dosing schedule and an analysis of treatment in diabetic sub-groups from the Phase 2a Part A clinical program evaluating BOS-580 for the treatment of non-alcoholic steatohepatitis (NASH), at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place November 10-14, 2023, in Boston.

Boston Pharmaceuticals today announced positive Phase 2a results for BOS-580, its investigational, proprietary, long-acting fibroblast growth factor 21 (FGF21) analog for the treatment of non-alcoholic steatohepatitis (NASH). The study suggested promising results for monthly and bi-weekly doses of BOS-580, which achieved statistically significant reduction in liver fat content, an exploratory endpoint in the trial of phenotypic NASH patients. Statistically significant reductions in additional exploratory endpoints, including biomarkers of liver injury and fibrosis, were also observed. In the trial, a low discontinuation rate due to treatment-emergent adverse events was observed. The most common adverse events in patients treated with BOS-580 were gastrointestinal in nature, mild to moderate, and transient. These and other results from the study were presented in a late-breaking poster at the European Association for the Study of the Liver (EASL 2023) International Liver Congress in Vienna, Austria.

Boston Pharmaceuticals today announced that new results from its ongoing Phase 2a study evaluating BOS-580 for the treatment of non-alcoholic steatohepatitis (NASH) were accepted as a late-breaking poster presentation at the European Association for the Study of the Liver International Liver Congress, June 21-24 in Vienna, Austria. BOS-580 is a genetically engineered variant of human fibroblast growth factor 21 (FGF21), administered via a monthly subcutaneous injection, that is designed to reduce liver fat, liver injury, and fibrosis in patients with NASH and improve other metabolic biomarkers.

Boston Pharmaceuticals, a clinical stage biopharmaceutical company, today announced the appointment of Dr. Sophie Kornowski as Chair of its Board of Directors and Acting Chief Executive Officer, effective immediately. Dr. Kornowski succeeds interim Co-CEOs Dr. Joanne T. Beck and Dr. Craig T. Basson, who will continue in their positions as Chief Operations Officer and Chief Medical Officer, respectively. Since 2018, Sophie Kornowski has been a partner at Gurnet Point Capital, a private investment firm focused on the healthcare sector. In this role, she has worked closely with the Boston Pharmaceuticals team for several years, as a member of the Board of Directors and, at the request of the Board, has recently supported Corporate Development efforts.

Boston Pharmaceuticals today announced administration of BOS-580 to the first patient in a Phase 2a clinical trial in individuals with nonalcoholic fatty liver disease and/or nonalcoholic steatohepatitis (NAFLD and/or NASH). BOS-580 is designed to be a form of FGF21 that regulates various metabolic pathways to decrease liver fat and ameliorate liver inflammation and damage in patients with NASH.

Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) and Boston Pharmaceuticals today announced that the companies have entered into an exclusive product license agreement to develop PRS-342, a 4-1BB/GPC3 preclinical immuno-oncology Anticalin®-antibody bispecific fusion protein. Under the terms of the agreement, Boston Pharmaceuticals has exclusively licensed worldwide rights to PRS-342. Pieris will receive an upfront payment of $10 million and is further entitled to receive up to approximately $353 million in development, regulatory, and sales-based milestone payments, and tiered royalties on sales of PRS-342. Pieris will also contribute an undisclosed amount toward manufacturing activities.